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Previewssuppression could shed light on new anti-
cancer strategies that inhibit the activation
of wild-type Ras by restoring expression
of the corresponding RasGAP.
Intriguingly, despite the fact that each
of the RasGAP members harbors a
conservedRasGAPdomain, not all exhibit
tumor suppressor functions (Min et al.,
2010). Accordingly, the existence of non-
Ras-associated functions of RasGAPs
has been proposed and further demon-
strated in the case of DAB2IP (Min et al.,
2010), which acts as a signaling scaffold
that coordinately regulates Ras and NF-
kB activation to promote tumor growth
and metastasis (Figure 1C), respectively.
Whether other conserved domain(s) be-
sides the RasGAP domain of RASAL2
also exert a Ras-independent tumor-sup-
pressive signaling cascade remains to be
investigated. Additionally, how the Ras-
GAPs coordinate with each other to regu-
late the activation of Ras in differenthuman cancers is not clear. Epigenetic
suppression of DAB2IP (Dote et al.,
2004) and the mutation of NF1 (The Can-
cer Genome Atlas Database) are also
observed in breast cancers, raising the
question of whether the deregulation
events of RasGAPs aremutually exclusive
or whether they coexist for sufficient
addiction to wild-type Ras activation in
breast cancer.REFERENCES
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Cancer cells display lysosome hypertrophy, secreting lysosomal hydrolases for tumor progression. Hyper-
trophy renders lysosomes fragile, increasing lysosomal membrane permeabilization (LMP) tendency. In
this issue of Cancer Cell, Petersen and colleagues show that lysosomal sphingomyelin content determines
LMP and cationic drugs displace acid sphingomyelinase from lysosomal membranes, increasing tumor
LMP and death.Early on after the discovery of lysosomes
by Christian de Duve as a separate com-
partment that confines highly destructive
hydrolases for the demolition and reuti-
lization of cellular substituents, the
concept that these structures might
alternatively represent ‘‘suicide bags’’
was proposed (de Duve, 1983). This led
to an intense search for lysosomatrophic
agents that might access this biology
for therapeutic purpose. Although a set
of lysosomal detergents with long hydro-
phobic tails and medium pK were defined
as capable of inducing lysosomal mem-brane permeabilization (LMP) and thereby
releasing the destructive power of hydro-
lases into the cytoplasm, this concept
was rapidly retired, because it was not
possible to assign lethal causality to
these compounds based on LMP as
opposed to postmortal lysosomal des-
truction (Miller et al., 1983).
In the interim, the field of cathepsin
protease biology developed. Cathepsins
represent a class of cysteine, serine, and
aspartate proteases that segregate into
lysosomes and, under homeostatic con-
ditions, serve to reutilize polypeptidesfor ongoing cellular metabolic require-
ments. Lysosomes contain more than
50 cathepsins, and, as a class, they
have been associated with various human
pathologies, including cancer. Numerous
cathepsins and other lysosomal enzymes,
e.g., heparanase, have been strongly
associated with cancer cell proliferation,
angiogenesis, and metastasis (Kallunki
et al., 2013). Evidence indicates that,
upon secretion, these tumor-promoting
lysosomal enzymes act extracellularly.
To accommodate this burgeoning need,
tumor cells in general display enlargementeptember 9, 2013 ª2013 Elsevier Inc. 279
Figure 1. Mechanism of CAD Effect on LMP
Left: tumor cell lysosomes contain lower SM levels than normal cell lysosomes and a compensatory lower
ASM activity.
Right: CADs functionally inhibit ASM by physico-chemical mechanisms. CADs are weak bases with a
cationic center and a lipophilic portion. The unprotonated form of the drug crosses membranes. Within
the highly acidic lysosomal compartment, the cationic part of the drug is protonated, trapped, and
concentrated. The lipophilic part of CADs folds into the lysosomal membrane, while the protonated
part of the molecule displaces positively-charged ASM from the negatively-charged inner lysosomal
membrane surface, resulting in proteolytic degradation of ASM within the lysosomal lumen (Hurwitz
et al., 1994). In ASM-reduced tumor cells, further reduction in ASM by CADs increases lysosomal SM
concentration, which destabilizes the already fragile tumor cell lysosomal membrane, contributing to
LMP and cell death. Normal cells do not undergo CAD-induced LMP. ASM also localizes to secretory
lysosomes, the cell surface, and is secreted (Henry et al., 2013). Surface forms of ASM are often pro-
apoptotic for various anticancer treatments. Surface ASM resides in acidic plasma membrane sub-
domains and is inhibited by CADs. Thus, use of CADs to antagonize lysosomal ASM will have to assess
the potential negative impact of this class of drugs on this therapeutic biology.
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Previewsof the lysosomal compartment. Mounting
evidence for a role of lysosomal constitu-
ents in tumor progression has spawned
numerous preclinical and clinical efforts
to abort lysosomal enzyme action (Kal-
lunki et al., 2013).
More recently, the focus has been on
the notion that this expanded lysosomal
compartment might represent a tumor
vulnerability (Kallunki et al., 2013). Sub-
stantive data indicate that tumor cell
lysosomes are more fragile than normal
lysosomes, i.e., they aremore susceptible
to LMP, leading to tumor demise by
apoptotic and nonapoptotic death mech-
anisms. This lysosome fragility is posited
(at least in part) to result from the extra
burden of destructive enzymes contained
within tumor cell lysosomes. Petersen
et al. (2013; in this issue of Cancer Cell)
have been major proponents of this latter280 Cancer Cell 24, September 9, 2013 ª201concept over the past decade. Work by
Petersen et al. (2013) and Kirkegaard
et al. (2010; in a recent publication in
Nature), have made the novel observation
that the sphingomyelin (SM) content of
lysosomal membranes regulates mem-
brane fragility and thus tendency toward
LMP. Initial studies focused on the
mechanism for the lysosome protective
effect of HSP70. Kirkegaard et al. (2010)
first tracked the trafficking of recombinant
fluorescent HSP70 into lysosomal mem-
branes. They determined that HSP70
bound preferentially to the endolysoso-
mal membrane-specific anionic lipid,
bis(monoacylglycer)phosphate (BMP).
Because Konrad Sandhoff had previously
shown that BMP binds acid sphingomye-
linase (ASM) with high affinity (Linke et al.,
2001), thereby stimulating the enzymatic
hydrolysis of SM to ceramide, Petersen3 Elsevier Inc.et al. (2013) made the conceptual leap
that SM metabolism might regulate LMP.
In a tour de force set of investigations,
they showed that HSP70 binding to BMP
stabilized the BMP-ASMase interaction,
thereby lowering lysosomal membrane
SM levels, which reduced membrane
fragility (Kirkegaard et al., 2010). An argu-
ment was thereafter made that HSP70
might be used therapeutically to stabilize
point-mutated ASM in Niemann-Pick dis-
ease, an inherited disorder characterized
by SM accumulation in lysosomes, lyso-
somal fragility, and either a progressive
neurodegenerative course (type A) or
progressive visceral organ abnormalities
(type B).
With these observations in hand and
the emerging data suggesting that cancer
cells manifest lysosomal traits analogous
to those of NPD patients, Petersen et al.
(2013) began to explore the potential of
attacking tumor cells by engaging SM
metabolism. This group had been inves-
tigating the capability of the cationic
drug (CAD) siramesine to induce LMP
and cell death of tumor cells (Ostenfeld
et al., 2005) and applied the lessons
learned from HSP70 lysosomal biology
to tumors (Figure 1). Using vector- and
c-srcY527F-transduced NIH 3T3 murine
embryonic fibroblasts (MEFs), evidence
was provided that the hypersensitivity of
the c-src-transduced MEFs to siramesine
was distinct from that of sphingosine and
Leu-LeuOMe, lysosomotropic detergents
that also induce LMP, and was not due to
neutralization of lysosomal pH per se.
Rather, it appeared that siramesine acted
like some other CADs that had been
recently shown to displace ASM from
the inner lysosomal membrane, resulting
in hydrolytic cleavage of ASM. In fact,
siramesine treatment leads to decreased
ASM activity and increased SM content
in c-src-transduced, but not vector-
transduced, NIH 3T3 MEFs, rendering
these SM-replete lysosomes susceptible
to LMP and cell death. This susceptibility
to siramesine appeared generic to tumor
cells as compared to detransformed
variants or isogenic normal cell lines. In a
large set of in vitro and in vivo models,
CADs, as a class, reproducibly antago-
nized tumor formation, growth, and/or
metastases.
From these data, it might have been
predicted that tumor cells would ubiqui-
tously display low levels of lysosomal
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lysosomal SM, thereby rendering their
lysosomal membranes exceptionally
fragile. Counterintuitively, studies in cell
culture and published data indicated that
diverse tumors actually display reduced
SM content. Sequencing three pairs of
vector- and c-src-transduced NIH 3T3
MEFs revealed the reduction of both
ASM and neutral sphingomyelinase
(NSM). Consistent with this observation,
a search of public microarray databases
revealed that human tumor tissues
generically display reduced ASM and
NSM. The authors conclude from these
data that the primary event must be
reduction in SM levels by an unknown
mechanism, followed by secondary
reduction in sphingomyelinases. It was
proposed that this generic SM reduction
compensated for the fragility of the
expanded tumor lysosomal compartment
chronically exposed to excess destruc-
tive hydrolases. This speculation must
eventually be addressed experimentally.
As a consequence of this unique biology,
Petersen et al. (2013) hypothesized that
the low levels of lysosomal ASM might
render tumor cells particularly sensitive
to stoichiometric inactivation by CADs
and subsequent LMP-induced tumor cell
death.
Studies using cells with multi-drug
resistance (MDR) due to ABCB1 overex-
pression support the hypothesis thattargeting lysosomal SM levels might
represent a novel therapeutic strategy.
Published data showed MDR improved
by CADs, and, in 1995, Levade noted
that this correlated with ASM inhibition
(Jaffre´zou et al., 1995). Because ABCB1
is a physiologic transporter of sphingoli-
pids, it was not entirely surprising that
MDR variants of the PC3 and DU145
prostate cancer lines displayed higher
ASM levels and activity than the parental
lines. What is exciting about the current
publication is the observation that, in
addition to siramesine antagonizing
MDR, siRNA to SMPD1, the ASM gene,
was as effective as siRNA to ABCB1 in
reverting the MDR phenotype.
The question of how to approach these
new concepts clinically remains. Because
CADs are well represented in the phar-
macologic armamentarium, with millions
of patients being prescribed tricyclic
antidepressant, calcium channel blocker,
and antihistamine CADs, it seems unlikely
that a potent antitumor effect would have
gone unnoticed. Perhaps a retrospective
analysis will be revealing. Alternatively,
perhaps the range of doses required
for the diverse clinical applications of
these drugs are insufficient for LMP,
which would represent a toxicity of this
drug class. Thus, it may be important to
select CADs with potent LMP-inducing
capabilities to take forward into the
clinic. Ultimately, CAD drug scheduling,Cancer Cell 24, Sdosing, and combination with chemo-
therapeutics will have to be addressed
if these concepts of SM-based LMP
therapy are to be effectively tested
clinically.REFERENCES
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